LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers Identified for Type 2 Diabetes

By LabMedica International staff writers
Posted on 24 Oct 2012
Print article
Novel biomarkers have been identified for type 2 diabetes that can serve as basis for developing new methods of treatment and prevention of this metabolic disease.

Metabolites in the blood have been characterized that will provide insight into the pathological mechanisms of type 2 diabetes and in addition can be used as biomarkers to determine the disease risk.

A scientific team at the German Institute of Human Nutrition (Potsdam-Rehbruecke, Germany) and the Max Delbrueck Center for Molecular Medicine (Berlin, Germany) studied 4,000 blood samples. At the time the blood sample was taken, none of the study participants suffered from type 2 diabetes. However, during the average follow-up time of seven years, 891 participants were diagnosed with type 2 diabetes. There were 76 participants in the study who were already classified at the beginning of the study as individuals at high risk for type 2 diabetes, but at the time the blood sample was taken, they were still healthy.

Flow injection analysis tandem mass spectrometry was used to quantify 163 metabolites per blood sample, including acylcarnitines, amino acids, hexose, and phospholipids, in baseline serum samples. Serum hexose; phenylalanine; and diacyl-phosphatidylcholines C32:1, C36:1, C38:3, and C40:5 were independently associated with increased risk of type 2 diabetes. Serum glycine; sphingomyelin C16:1; acyl-alkyl-phosphatidylcholines C34:3, C40:6, C42:5, C44:4, and C44:5; and lysophosphatidylcholine C18:2 were associated with decreased risk.

The metabolites significantly improved type 2 diabetes prediction compared with established risk factors. They were further linked to insulin sensitivity and secretion in one study group and were partly replicated in the independent cohort. The data indicate that metabolic alterations, including sugar metabolites, amino acids, and choline-containing phospholipids, are associated early on with a higher risk of type 2 diabetes.

Tobias Pischon, MD MPH, the lead author, said “At the same time the metabolites can also be used as biomarkers to precisely determine the risk of diabetes at a very early stage, since the study is based on prospective data, which is data that were collected before the onset of the disease. The results of the new metabolomic analysis thus provide a good basis for developing new treatment and prevention methods." The study was published on October 4, 2012, in the journal Diabetes.

Related Links:

German Institute of Human Nutrition
Max Delbrueck Center for Molecular Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more